diphenylhydantoin sodium

(redirected from Phenytoin sodium)
Also found in: Thesaurus, Medical, Encyclopedia.

diphenylhydantoin sodium

(daɪˌfiːnaɪlhaɪˈdæntəʊɪn; -nɪl-; -ˌfɛn-)
n
(Pharmacology) another name for phenytoin
Mentioned in ?
References in periodicals archive ?
The British Court of Appeal has upheld Flynn Pharma's right to stop the parallel importation of Pfizer's (NYSE: PFE) Epanutin (phenytoin sodium) anti-epileptic drug into the UK for resale as Phenytoin Sodium Flynn, the company announced on Thursday.
The Mylan version is packaged in 100 mg phenytoin sodium equivalent/10 mL single-use vials.
A single 100 mg phenytoin sodium capsule was opened and placed in 5 mL of sterile normal saline to form a suspension.
2] Phenytoin sodium is the most frequently administered anticonvulsant, due to its high therapeutic efficacy and cost-effectiveness.
THE NHS has been overcharged by tens of millions of pounds for years for an anti-epilepsy drug, a watchdog has claimed Pfizer and Flynn Pharma were accused of abusing their stranglehold on phenytoin sodium capsules, with the NHS bill soaring from PS2.
The Competition and Markets Authority (CMA) said it is investigating whether or not Pfizer and Flynn Pharma abused their dominant position over the pricing of phenytoin sodium capsules, in breach of UK and EU competition law.
Fosphenytoin is measured in phenytoin sodium equivalents (PEs).
Phenytoin sodium (Dilantin[R]) - Parke-Davis) is an agent used for the treatment of acute seizures and status epilepticus.
Fosphenytoin Sodium Injection is a prodrug of Phenytoin Sodium and is indicated in the short term use for the prevention and control of generalized seizures occurring during neurosurgery.
This is one of a number of CMA cases in the pharmaceutical sector, including a recent fine against Pfizer and Flynn Pharma of nearly 90 million in relation to excessive and unfair prices for anti-epilepsy treatment, phenytoin sodium capsules, in respect of which the CMAs decision is currently under appeal.
The regulatory agency alleges that the two companies removed the official brand name, Epanutin, from Pfizer's phenytoin sodium capsule product in 2012, rendering it a generic so they could increase the price by as much as 2,600% to the U.